Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Hu, Zheng ^a   Pan, Xiao Fen ^a   Wu, Fu Qun ^a   Ma, Li Yuan ^b   Liu, Da Peng ^a   Feng, Ting Ting ^a,c   Meng, Fan Yi ^d   Liu, Xiao Li ^d   Jiang, Qian Li ^d   Chen, Xiao Qin ^e   Liu, Jing Lei ^a,c   Liu, Ping ^b   Chen, Zhu ^b   Chen, Sai Juan ^b   Zhou, Guang Biao ^a,f  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d FIRST MILITARY MEDICAL UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; BORTEZOMIB; BRUTON TYROSINE KINASE; CASPASE; CYTOCHROME C; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEASOME; PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME REACTIVATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIFESPAN; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; POSITIVE FEEDBACK; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MICE, NUDE; PIPERAZINES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRIMIDINES; RNA INTERFERENCE;

EID: 67650888562     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006257     Document Type: Article

References (71)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med 344: 1031-1037.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. (2003) Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N Engl J Med 348: 994-1004.
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. N Engl J Med 344: 1038-1042.
5. Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843.
6. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
7. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
8. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698.
9. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652.
10. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539.
11. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928-1937.
12. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332-344.
13. Park YH, Park HJ, Kim BS, Ha E, Jung KH, et al. (2006) BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 243: 16-22.
14. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, et al. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916.
15. Noren NK, Foos G, Hauser CA, Pasquale EB (2006) The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8: 815-825.
16. Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6: 79-87.
17. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, et al. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333-338.
18. Traenckner EB, Wilk S, Baeuerle PA (1994) A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 13: 5433-5441.
19. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, et al. (2003) A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N Engl J Med 348: 2609-2617.
20. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. (2005) Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med 352: 2487-2498.
21. Servida F, Soligo D, Delia D, Henderson C, Brancolini C, et al. (2005) Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 19: 2324-2331.
22. Soligo D, Servida F, Delia D, Fontanella E, Lamorte G, et al. (2001) The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 113: 126-135.
23. Yu C, Rahmani M, Conrad D, Subler M, Dent P, et al. (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102: 3765-3774.
24. Dai Y, Rahmani M, Pei XY, Dent P, Grant S (2004) Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/ Abl-dependent and -independent mechanisms. Blood 104: 509-518.
25. Gatto S, Scappini B, Pham L, Onida F, Milella M, et al. (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/ Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88: 853-863.
26. Dou QP, McGuire TF, Peng Y, An B (1999) Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 289: 781-790.
27. Zhang X, Ren R (1998) Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92: 3829-3840.
28. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104.
29. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, et al. (1999) In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor. J Natl Cancer Inst 91: 163-168.
30. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, et al. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000.
31. Zhou GB, Kang H, Wang L, Gao L, Liu P, et al. (2007) Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109: 3441-3450.
32. Yin T, Wu YL, Sun HP, Sun GL, Du YZ, et al. (2004) Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104: 4219-4225.
33. Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15: 342-347.
34. Chou TC, Talalay P (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216.
35. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, et al. (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8: 355-368.
36. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
37. Chauhan D, Catley L, Li G, Podar K, Hideshima T, et al. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8: 407-419.
38. Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, et al. (2007) Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21: 84-92.
39. Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, et al. (2007) Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 26: 1456-1466.
40. Bonnet S, Archer SL, lalunis-Turner J, Haromy A, Beaulieu C, et al. (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37-51.
41. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, et al. (2001) Novel Role for JNK as a Stress-activated Bcl2 Kinase. J Biol Chem 276: 23681-23688.
42. Di Bacco AM, Cotter TG (2002) p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. Br J Haematol 117: 588-597.
43. Stewart MJ, Litz-Jackson S, Burgess GS, Williamson EA, Leibowitz DS, et al. (1995) Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia 9: 1499-1507.
44. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-3804.
45. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
46. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
47. Villuendas R, Steegmann JL, Pollan M, Tracey L, Granda A, et al. (2006) Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 20: 1047-1054.
48. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, et al. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. PNAS 104: 13283-13288.
49. Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, et al. (2008) Proteasome dependent auto-regulation of Bruton's tyrosine kinase (Btk) promoter via NF-{kappa}B. Blood 111: 4617-4626.
50. LaMontagne KR Jr., Hannon G, Tonks NK (1998) Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of Rat-1 fibroblasts and promotes differentiation of K562 cells. PNAS 95: 14094-14099.
51. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, et al. (2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62.
52. Trockenbacher A, Suckow V, Foerster J, Winter J, Krausz S, et al. (2001) MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nat Genet 29: 287-294.
53. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, et al. (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117: 2408-2421.
54. Schellings MWM, Baumann M, van Leeuwen REW, Duisters RFJJ, Janssen SHP, et al. (2006) Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 Rats. Hypertension 47: 467-474.
55. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, et al. (2004) Imatinib Attenuates Diabetes-Associated Atherosclerosis. Arterioscler Thromb Vasc Biol 24: 935-942.
56. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
57. Saad SY, Alkharfy KM, Arafah MM (2006) Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol 58: 567-573.
58. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270.
59. Magill L, Lynas J, Morris TC, Walker B, Irvine AE (2004) Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma. Haematologica 89: 1428-1433.
60. Heaney N, Pellicano F, Crawford L, Irvine S, Holyoake TL (2007) Bortezomib Has Anti-Proliferative and Apoptotic Effects Against CML Stem Cells, Including the Quiescent Population. ASH Annual Meeting Abstracts 110: 2943.
61. Voortman J, Giaccone G (2006) Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 6: 129.
62. Hacihanefioglu A, Tarkun P, Gonullu E (2008) Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 88: 219-222.
63. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, et al. (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138: 396-397.
64. Sanchez-Garcia I, Grutz G (1995) Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 92: 5287-5291.
65. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977-984.
66. marante-Mendes GP, Naekyung KC, Liu L, Huang Y, Perkins CL, et al. (1998) Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91: 1700-1705.
67. Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M, et al. (2004) Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol 24: 10289-10299.
68. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398.
69. Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, et al. (2004) Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML. N Engl J Med 351: 657-667.
70. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, et al. (2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541.
71. Seeling JM, Miller JR, Gil R, Moon RT, White R, et al. (1999) Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 283: 2089-2091.